blue and black abstract painting

Actym Therapeutics and Wacker Biotech Sign Contract for Solid Tumor Treatment Candidate

PRESS RELEASE — Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors. Under the terms of the …

Actym Therapeutics and Wacker Biotech Sign Contract for Solid Tumor Treatment Candidate Read More »